[Boston Business Journal] With both positive momentum and the competitive stakes so high, companies with the most knowledge, the greatest experience targeting innovative assets — and those that employ rapid and thorough due diligence — can prevail in this deal market.
KPMG and MassBio on aligning financial management systems with biotech lifecycles: From pre-commercial to high-growth
Video Series: Disruption in Life Sciences (ft. Mary Rollman, KPMG)
An open forum for business leaders across the industry to share perspectives, gain insight, develop approaches to help balance risk and improve performance.
Led by a nationally-recognized team of life science experts, the KPMG New England Life Sciences Center helps clients address their most complex challenges. From strategy to execution and from early-stage to IPO and beyond, our team collaboratively works with senior executives to create a lasting, meaningful impact across three areas of focus:
Growth, Profit, and Protection
Regional Industry Leaders
Global and National Strategy and Deal Advisory Leader, Healthcare and Life Sciences, KPMG LLP
+1 617 549 2779
Managing Director, Healthcare and Life Sciences Strategy, KPMG US
+1 617-988-5419
Principal, Advisor/Supply Chain Strategy and Life Sciences Lead, KPMG US
+1 312-618-9863
[Video] David Frey from KPMG and Mike Kennealy, Mass. Secretary of Housing and Economic Development, connect to discuss how the life sciences sector expanding to outlying communities is creating additional regional clusters of biotech innovation in the area.
Find your fit with our team in New England and Upstate New York!
[Boston Business Journal] With both positive momentum and the competitive stakes so high, companies with the most knowledge, the greatest experience targeting innovative assets — and those that employ rapid and thorough due diligence — can prevail in this deal market.
